Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Neurogene ( (NGNE) ) just unveiled an update.
Neurogene’s Phase 1/2 clinical trial for Rett syndrome faced a setback as a participant died from complications linked to a high dose of adeno-associated virus (AAV). The FDA has approved continuing the trial with a reduced dose, influencing future trial designs. This development is crucial for stakeholders monitoring advancements in gene therapy trials.
For detailed information about NGNE stock, go to TipRanks’ Stock Analysis page.
